AlphAIAlphAI — Financial news for AI agents
financialcontent.com$HAE

Haemonetics (HAE) Shares Skyrocket, What You Need To Know

Haemonetics (HAE) shares rose 12.4% after CSL Plasma announced plans to fully deploy NexSys PCS devices in U.S. centers by 2027. Haemonetics maintained its fiscal 2027 guidance. The company's stock has seen volatility, with a 22.1% gain 11 months ago on strong Q3 results. HAE is up 43.8% YTD, hitting a 52-week high of $114.99.

Original reporting
financialcontent.com
Published Oct 8, 2026, 2:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 3:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Haemonetics (HAE) Shares Skyrocket, What You Need To Know — source image
Source · financialcontent.com
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

The contract expands Haemonetics' market footprint and may accelerate consumable revenue growth.

02

Market read

The announcement triggered a double‑digit stock move, indicating immediate market relevance for traders.

03

What to watch

Potential competition from alternative collection technologies and the capital intensity of scaling the device network.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Haemonetics provides blood‑collection equipment; CSL Plasma is a major U.S. plasma collector.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Shares jumped 12.4% after CSL Plasma announced full deployment of Haemonetics' NexSys PCS devices across its U.S. collection centers.

Expected impact

upward pressure as investors price in higher multi‑year demand for equipment and disposables.

Evidence & confidence

A 12% same‑day move on a concrete contract award signals strong market reaction; the rollout covers an extensive network, indicating sizable revenue upside.

Market effects

Sector

Positive for medical device and blood‑collection equipment sector as a major plasma operator expands a key technology platform.

Regional

U.S. plasma collection industry may see increased supplier demand, boosting related service providers.

Global

Limited to U.S. market; no immediate global ripple but reinforces confidence in blood‑product supply chains.

Counterpoint

What could challenge this read

If the rollout faces operational delays or regulatory hurdles, the initial price surge could be short‑lived.

Key entities

  • Company
    Haemonetics

    Medical technology firm supplying blood‑collection devices.

  • Company
    CSL Plasma

    Operator of U.S. plasma collection centers.

Read at source← All news

StoryHaemonetics secures CSL Plasma rollout of NexSys PCS devices across U.S. centers by end‑2027

Also covered by

6 outlets

Related articles

$HAEMedAI 8/10

Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded

Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.

finance.yahoo.com
$HAEHighAI 8/10

Haemonetics Corporation Q2 2027 Earnings Call Summary

Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.

finance.yahoo.com
$HAEMedAI 8/10

Haemonetics (HAE) Q2 2027 Earnings Call Transcript

Haemonetics reported Q2 2027 earnings, highlighting 6% organic growth in MedSurg and 14% in Apheresis. Key drivers include TEG 6s disposables, VASCADE products, and Persona PLUS adoption. The company raised its fiscal 2027 revenue guidance to 6%-9% organic growth and 8%-11% reported growth, citing strong first-half performance and increased visibility into customer commitments.

finance.yahoo.com
$HAEMed

Mizuho raises Haemonetics stock price target on plasma strength

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

investing.com
$HAEHighAI 8/10

BTIG raises Haemonetics stock price target to $142 on earnings beat

BTIG raised its price target on Haemonetics (HAE) to $142 from $130, maintaining a Buy rating. HAE's Q2 2027 revenue was $357.8M, up 9.3% YoY, beating estimates. Adjusted EPS was $1.35, exceeding expectations. All segments performed well, with Apheresis revenue at $204.8M. Adjusted gross margin increased to 61.9%. HAE raised fiscal 2027 revenue guidance but reduced adjusted EBIT margin expansion outlook.

investing.com